Work

Advancing Group A Streptococcus vaccines: barriers, models, and the path to rheumatic fever prevention

Year: 2026

Type: article

Abstract: Group A Streptococcus (GAS; Streptococcus pyogenes) remains a leading global cause of infectious and post-infectious disease and a substantial annual burden of pharyngitis, invasive disease, and immune-mediated sequelae.1 Acute rheumatic fever (ARF) and its chronic sequelae, rheumatic heart disease (RHD), disproportionately affect children and young adults in low- and middle-income countries and marginalised populations in high-income settings.2 To date, no licensed vaccine against GAS is available, and diagnostic tools for ARF remain scarcely available.

Source: The Lancet Microbe

DOI: 10.1016/j.lanmic.2026.101495

Authors: Mark J Walker, Stephan Brouwer

Institutions: The University of Queensland, Institute for Molecular Bioscience

Language: English

Topic: Streptococcal Infections and Treatments

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $7,280